Skip to main content
. 2021 May 5;13(5):661. doi: 10.3390/pharmaceutics13050661

Figure 4.

Figure 4

Effects of PDC on tumor growth using a mouse model of TNBC. NOD-SCID female mice bearing xenograft human MDA-MB-231 tumors were treated with PDC (2.5 mg Dox equiv./kg), Dox (2.5 mg/kg), or saline (0.9% normal saline). (a) Tumor volumes measured over the duration of treatment. The treatment regimen included six tail-vein injections administered weekly (as indicated by arrows). Results are presented as mean ± SD; n = 7; * p < 0.05, *** p < 0.001, Student t-test and one-way ANOVA test (at day 30 or day 35); (b) Average body weight of mice for each treatment group. Results are presented as mean ± SD; n = 7; ** p < 0.01, Student t-test and one-way ANOVA test (at day 32); (c) average tumor weight after mice were euthanized and tumors collected. Results are presented as mean ± SD; n = 7; ** p < 0.01, ns non-significant, Student t-test and one-way ANOVA test. (RHS of c) representative images of the tumor xenografts collected from three groups.